ADCs

Therapy Areas

Drug Classes

Therapy Areas

All Sessions

Resectable NSCLC

Advanced NSCLC

SCLC

Biomarkers

Drug Classes

Targeted Therapies

Immunotherapies

All

FEATURED

ILCS

Webinars

Articles

Industry Sponsored

Featured Sessions

Oct 05 2024

INDUSTRY SYMPOSIUM

Advanced NSCLCADCs

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard

From Our Annual Summit

ILCS Sessions

Sep 26 2025

ILCS 2025

ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

The Emerging Role of ADCs: Navigating Timing and Applications for Optimal Use

} 20 min

J. Naidoo

Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Dec 18 2025

VIRTUAL ROUNDTABLE

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

The Reading Room

Articles & Research

Sep 30 2026

RESEARCH

Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

Ris-Rez improved OS against topotecan in relapsed SCLC in China

Sep 16 2026

CONGRESS

Advanced NSCLCADCs

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Sep 14 2026

CONGRESS

Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 14 2026

CONGRESS

Advanced NSCLCADCs

DESTINY-Lung04: first-line T-DXd adds six months of PFS, no interim survival gain

Sep 13 2026

CONGRESS

SCLCADCs

ARTEMIS-008: risvutatug rezetecan lifts relapsed-SCLC survival to 18.5 months

Sep 13 2026

CONGRESS

Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months

Sep 13 2026

CONGRESS

Advanced NSCLCADCsImmunotherapies

EVOKE-03: sacituzumab govitecan plus pembrolizumab misses both primary endpoints

Tam-Peli extends overall survival over topotecan in relapsed SCLC: TAISHAN-302

Sep 12 2026

CONGRESS

Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Aug 29 2026

RESEARCH

Advanced NSCLCADCs

International panel sets 55 consensus recommendations for managing Dato-DXd side effects in NSCLC

S. Saw

Aug 27 2026

RESEARCH

Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara

Aug 07 2026

RESEARCH

Advanced NSCLCBiomarkersADCs

EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel

Sac-TMT plus pembrolizumab improves PFS in PD-L1-negative NSCLC

Jul 14 2026

RESEARCH

Advanced NSCLCADCs

Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date

M. HochmairG. MountziosA. AddeoM. Reck

Jul 14 2026

RESEARCH

Advanced NSCLCSCLCADCs

ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities

R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon

Industry Sponsored

Featured Sessions

Oct 05 2024

INDUSTRY SYMPOSIUM

Advanced NSCLCADCs

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard

From Our Annual Summit

ILCS Sessions

Sep 26 2025

ILCS 2025

ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

The Emerging Role of ADCs: Navigating Timing and Applications for Optimal Use

} 20 min

J. Naidoo

Expert Insights

Webinars

Dec 18 2025

VIRTUAL ROUNDTABLE

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

The Reading Room

Articles & Research

Sep 30 2026

RESEARCH

Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

Ris-Rez improved OS against topotecan in relapsed SCLC in China

Sep 16 2026

CONGRESS

Advanced NSCLCADCs

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Sep 14 2026

CONGRESS

Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 14 2026

CONGRESS

Advanced NSCLCADCs

DESTINY-Lung04: first-line T-DXd adds six months of PFS, no interim survival gain

Sep 13 2026

CONGRESS

SCLCADCs

ARTEMIS-008: risvutatug rezetecan lifts relapsed-SCLC survival to 18.5 months

Sep 13 2026

CONGRESS

Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months

Sep 13 2026

CONGRESS

Advanced NSCLCADCsImmunotherapies

EVOKE-03: sacituzumab govitecan plus pembrolizumab misses both primary endpoints

Tam-Peli extends overall survival over topotecan in relapsed SCLC: TAISHAN-302

Sep 12 2026

CONGRESS

Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Aug 29 2026

RESEARCH

Advanced NSCLCADCs

International panel sets 55 consensus recommendations for managing Dato-DXd side effects in NSCLC

S. Saw

Aug 27 2026

RESEARCH

Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara

Aug 07 2026

RESEARCH

Advanced NSCLCBiomarkersADCs

EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel

Sac-TMT plus pembrolizumab improves PFS in PD-L1-negative NSCLC

Jul 14 2026

RESEARCH

Advanced NSCLCADCs

Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date

M. HochmairG. MountziosA. AddeoM. Reck

Jul 14 2026

RESEARCH

Advanced NSCLCSCLCADCs

ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities

R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon